JY
SLS icon

Jeff Yass’s SELLAS Life Sciences SLS Stock Holding History

Jeff Yass’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61.8M Buy
4,189,200
+3,228,800
+336% +$22.3M ﹤0.01% 1333
2026
Q1 		$4.06M Buy
960,400
+683,700
+247% +$3.06M ﹤0.01% 4628
2025
Q4 		$1.04M Buy
276,700
+216,400
+359% +$421K ﹤0.01% 7090
2025
Q3 		$97.1K Buy
60,300
+34,000
+129% +$60.6K ﹤0.01% 11582
2025
Q2 		$57.6K Buy
+26,300
New +$40.4K ﹤0.01% 12071
2025
Q1 		– Sell
-21,000
Closed -$21.8K – 13375
2024
Q4 		$21.8K Buy
+21,000
New +$24K ﹤0.01% 11900
2024
Q3 		– Sell
-44,600
Closed -$53.1K – 12948
2024
Q2 		$53.1K Buy
44,600
+21,500
+93% +$29.3K ﹤0.01% 11389
2024
Q1 		$23.3K Sell
23,100
-7,300
-24% -$6.13K ﹤0.01% 11784
2023
Q4 		$32.2K Buy
+30,400
New +$32.9K ﹤0.01% 11861
2023
Q2 		– Sell
-10,600
Closed -$15.2K – 13046
2023
Q1 		$15.2K Sell
10,600
-800
-7% -$1.98K ﹤0.01% 12116
2022
Q4 		$26.9K Sell
11,400
-13,400
-54% -$37.6K ﹤0.01% 11656
2022
Q3 		$50K Sell
24,800
-6,200
-20% -$17.1K ﹤0.01% 12206
2022
Q2 		$69K Sell
31,000
-86,600
-74% -$254K ﹤0.01% 11778
2022
Q1 		$786K Buy
117,600
+10,500
+10% +$61.4K ﹤0.01% 7767
2021
Q4 		$592K Sell
107,100
-4,200
-4% -$31.8K ﹤0.01% 8727
2021
Q3 		$1.02M Buy
111,300
+25,400
+30% +$236K ﹤0.01% 7514
2021
Q2 		$953K Buy
85,900
+29,100
+51% +$284K ﹤0.01% 7910
2021
Q1 		$485K Buy
+56,800
New +$465K ﹤0.01% 9542
2018
Q1 		– Sell
-16
Closed -$6K – 10108
2017
Q4 		$6K Sell
16
-1
-6% -$484 ﹤0.01% 9127
2017
Q3 		$9K Buy
17
+3
+21% +$1.98K ﹤0.01% 8689
2017
Q2 		$12K Sell
14
-42
-75% -$36.5K ﹤0.01% 9064
2017
Q1 		$51K Sell
56
-109
-66% -$180K ﹤0.01% 8588
2016
Q4 		$479K Buy
+165
New +$959K ﹤0.01% 7084

Other funds holding SLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 374.31% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jeff Yass's SLS Position: Q2 2026 in Review

Jeff Yass increased its SELLAS Life Sciences (SLS) stake by 416% in Q2 2026, buying an estimated $11.4M and bringing the position to 2,050,597 shares worth $30.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2008.

Jeff Yass first reported a position in SLS in Q4 2016 and has held it in 19 quarters since. 190 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

  • Jeff Yass held 2,050,597 shares of SELLAS Life Sciences worth $30.3M as of Q2 2026.
  • Jeff Yass bought 1,653,541 SELLAS Life Sciences shares in Q2 2026, an estimated $11.4M.
  • SELLAS Life Sciences made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #2008 holding.
  • Jeff Yass first reported a position in SELLAS Life Sciences in Q4 2016 and has held it in 19 quarters since.
  • 190 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.